A share price of LENZ Therapeutics Inc [LENZ] is currently trading at $23.82, up 3.30%. An important factor to consider is whether the stock is rising or falling in short-term value. The LENZ shares have gain 28.48% over the last week, with a monthly amount drifted -6.66%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, TD Cowen started tracking the stock with Buy rating on March 18, 2025, and set its price target to $60. On September 27, 2024, Raymond James initiated with a Outperform rating and assigned a price target of $37 on the stock. H.C. Wainwright started tracking the stock assigning a Buy rating and suggested a price target of $38 on August 12, 2024. William Blair initiated its recommendation with a Outperform. Leerink Partners started tracking with a Outperform rating for this stock on April 15, 2024, and assigned it a price target of $32. In a note dated April 10, 2024, Citigroup initiated an Buy rating and provided a target price of $34 on this stock.
LENZ Therapeutics Inc experienced fluctuations in its stock price throughout the past year between $14.42 and $38.93. Currently, Wall Street analysts expect the stock to reach $51 within the next 12 months. LENZ Therapeutics Inc [NASDAQ: LENZ] shares were valued at $23.82 at the most recent close of the market. An investor can expect a potential return of 114.11% based on the average LENZ price forecast.
Analyzing the LENZ fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.23, Equity is -0.25 and Total Capital is -0.29. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.01.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 23.02 points at the first support level, and at 22.23 for the second support level. However, for the 1st resistance point, the stock is sitting at 24.60, and for the 2nd resistance point, it is at 25.38.
Ratios To Look Out For
To put it in perspective, the Current Ratio for LENZ Therapeutics Inc [NASDAQ:LENZ] is 20.36. On the other hand, the Quick Ratio is 20.36, and the Cash Ratio is 1.94.
Transactions by insiders
Recent insider trading involved Chevallard Daniel R., Chief Financial Officer, that happened on May 14 ’24 when 3188.0 shares were purchased. Director, MCCOLLUM JAMES W completed a deal on May 13 ’24 to buy 31332.0 shares.
